These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11122575)

  • 41. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
    Sanchez C; Reines EH; Montgomery SA
    Int Clin Psychopharmacol; 2014 Jul; 29(4):185-96. PubMed ID: 24424469
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Depressing misrepresentation?
    Newton J; Langlands A
    Lancet; 2004 May; 363(9422):1732. PubMed ID: 15158640
    [No Abstract]   [Full Text] [Related]  

  • 43. Benefits and harms of pediatric antidepressant medications.
    Edwards JL; Kirk KK; Midha CK
    JAMA; 2007 Aug; 298(6):626-7; author reply 627. PubMed ID: 17684183
    [No Abstract]   [Full Text] [Related]  

  • 44. Substance P in depression.
    Salzman C
    Harv Ment Health Lett; 2001 Dec; 18(6):7. PubMed ID: 11751091
    [No Abstract]   [Full Text] [Related]  

  • 45. Paroxetine in the treatment of Chinese patients with depressive episode: a double-blind randomized comparison with imipramine.
    Chiu HJ; Hong CJ; Chan CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 Jun; 57(6):418-23. PubMed ID: 8803304
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression.
    Mazeh D; Shahal B; Aviv A; Zemishlani H; Barak Y
    Int Clin Psychopharmacol; 2007 Nov; 22(6):371-5. PubMed ID: 17917556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Depression, selective serotonin reuptake inhibitors and bruxism.
    Hazara R
    Dent Update; 2015 Dec; 42(10):979. PubMed ID: 26856008
    [No Abstract]   [Full Text] [Related]  

  • 48. Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study.
    Amodeo L; Castelli L; Leombruni P; Cipriani D; Biancofiore A; Torta R
    Support Care Cancer; 2012 Feb; 20(2):375-84. PubMed ID: 21404089
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spotlight on paroxetine in psychiatric disorders in adults.
    Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
    CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Paroxetine in the treatment of generalised anxiety disorder.
    Snyderman SH; Rynn MA; Bellew K; Rickels K
    Expert Opin Pharmacother; 2004 Aug; 5(8):1799-806. PubMed ID: 15264994
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial.
    Paile-Hyvärinen M; Wahlbeck K; Eriksson JG
    BMC Fam Pract; 2003 May; 4():7. PubMed ID: 12747810
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Withdrawal syndromes after paroxetine and sertraline discontinuation.
    Fava GA; Grandi S
    J Clin Psychopharmacol; 1995 Oct; 15(5):374-5. PubMed ID: 8830071
    [No Abstract]   [Full Text] [Related]  

  • 53. [Selective serotonin reuptake inhibitors (SSRI's) are not indicated for children and adolescents with depression].
    Lekkerkerker JF; Schobben AF; van Dissel JT; Hekster YA; Hoes AW; Mulder GJ; Neef C; Peeters MF; van Ree JM; Rosmalen CF; Schellekens H; Schellens JH; Silberbusch J
    Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1870-1; author reply 1871-2. PubMed ID: 16128186
    [No Abstract]   [Full Text] [Related]  

  • 54. SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial.
    Grunebaum MF; Keilp JG; Ellis SP; Sudol K; Bauer N; Burke AK; Oquendo MA; Mann JJ
    J Clin Psychiatry; 2013 Sep; 74(9):872-9. PubMed ID: 24107760
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment.
    Capuron L; Neurauter G; Musselman DL; Lawson DH; Nemeroff CB; Fuchs D; Miller AH
    Biol Psychiatry; 2003 Nov; 54(9):906-14. PubMed ID: 14573318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
    J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Deciding which selective serotonin reuptake inhibitor to prescribe.
    Cleare AJ
    BMJ; 1995 Dec; 311(7020):1641. PubMed ID: 8555826
    [No Abstract]   [Full Text] [Related]  

  • 58. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.
    Ushiroyama T; Ikeda A; Ueki M
    J Med; 2004; 35(1-6):151-62. PubMed ID: 18084873
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression.
    Hicks JA; Argyropoulos SV; Rich AS; Nash JR; Bell CJ; Edwards C; Nutt DJ; Wilson SJ
    Br J Psychiatry; 2002 Jun; 180():528-35. PubMed ID: 12042232
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Quality of life as the criterion of psychological status of patients with painful dysfunction of the temporomandibular joint].
    Mamedov FM; Markov BP; Gorozhankina EA
    Stomatologiia (Mosk); 2004; 83(4):65-7. PubMed ID: 15340309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.